ImmunoGen’s Obvious Recent Progress

 ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results 

On April 28, 2023, ImmunoGen (IMGN) reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023. 

Immunogen's drug ELAHERE® (mirvetuximab soravtansine-gyn) is a first-in-class antibody drug conjugate (ADC) comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.